BAQSIMI Drug Patent Profile
✉ Email this page to a colleague
When do Baqsimi patents expire, and when can generic versions of Baqsimi launch?
Baqsimi is a drug marketed by Amphastar Pharms Inc and is included in one NDA. There are three patents protecting this drug.
This drug has eighty-three patent family members in forty-one countries.
The generic ingredient in BAQSIMI is glucagon. There are twelve drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the glucagon profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Baqsimi
A generic version of BAQSIMI was approved as glucagon by FRESENIUS KABI USA on May 8th, 2015.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BAQSIMI?
- What are the global sales for BAQSIMI?
- What is Average Wholesale Price for BAQSIMI?
Summary for BAQSIMI
International Patents: | 83 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Clinical Trials: | 2 |
Drug Prices: | Drug price information for BAQSIMI |
What excipients (inactive ingredients) are in BAQSIMI? | BAQSIMI excipients list |
DailyMed Link: | BAQSIMI at DailyMed |
US Patents and Regulatory Information for BAQSIMI
BAQSIMI is protected by three US patents.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amphastar Pharms Inc | BAQSIMI | glucagon | POWDER;NASAL | 210134-001 | Jul 24, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Amphastar Pharms Inc | BAQSIMI | glucagon | POWDER;NASAL | 210134-001 | Jul 24, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Amphastar Pharms Inc | BAQSIMI | glucagon | POWDER;NASAL | 210134-001 | Jul 24, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BAQSIMI
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Amphastar Pharms Inc | BAQSIMI | glucagon | POWDER;NASAL | 210134-001 | Jul 24, 2019 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for BAQSIMI
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Tetris Pharma B.V | Ogluo | glucagon | EMEA/H/C/005391 Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. |
Authorised | no | no | no | 2021-02-11 | |
Eli Lilly Nederland B.V. | Baqsimi | glucagon | EMEA/H/C/003848 Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus. |
Authorised | no | no | no | 2019-12-16 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for BAQSIMI
See the table below for patents covering BAQSIMI around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 3258919 | ⤷ Subscribe | |
Japan | 2019521050 | 流体製品吐出装置 | ⤷ Subscribe |
China | 113613671 | 药物递送系统和方法 (MEDICATION DELIVERY SYSTEMS AND METHODS) | ⤷ Subscribe |
World Intellectual Property Organization (WIPO) | 2016133863 | ⤷ Subscribe | |
Canada | 3130823 | SYSTEMES ET PROCEDES D'ADMINISTRATION DE MEDICAMENT (MEDICATION DELIVERY SYSTEMS AND METHODS) | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
BAQSIMI Market Analysis and Financial Projection Experimental
More… ↓